Pneumococcal conjugate second or third-dose vaccines (PCVc) in High income (World Bank)
High income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 87.0% in 2025. ▲ Rising
Latest (2025)
87.0%
Change on year
unchanged
Rank
2nd
of 11 groups
All-time high
90.0%
in 2019
All-time low
35.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in High income (World Bank), 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in High income (World Bank) stood at 87.0%.
The figure is up 20.8% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in High income (World Bank) peaked at 90.0% in 2019 and was at its lowest, 35.0%, in 2008.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in High income (World Bank), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 35.0% | — |
| 2009 | 42.0% | +20.0% |
| 2010 | 54.0% | +28.6% |
| 2011 | 65.0% | +20.4% |
| 2012 | 67.0% | +3.1% |
| 2013 | 68.0% | +1.5% |
| 2014 | 69.0% | +1.5% |
| 2015 | 72.0% | +4.3% |
| 2016 | 77.0% | +6.9% |
| 2017 | 84.0% | +9.1% |
| 2018 | 87.0% | +3.6% |
| 2019 | 90.0% | +3.4% |
| 2020 | 87.0% | -3.3% |
| 2021 | 87.0% | +0.0% |
| 2022 | 88.0% | +1.1% |
| 2023 | 88.0% | +0.0% |
| 2024 | 87.0% | -1.1% |
| 2025 | 87.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 38.5% | 35.0% | 42.0% | 2 |
| 2010s | 73.3% | 54.0% | 90.0% | 10 |
| 2020s | 87.3% | 87.0% | 88.0% | 6 |
Countries ranked near High income (World Bank)
- 1 Cook Islands 99.0% compare
- 1 Hungary 99.0% compare
- 1 Oman 99.0% compare
- 1 Bahrain 99.0% compare
- 1 Seychelles 99.0% compare
- 1 Bhutan 99.0% compare
- 1 Cuba 99.0% compare
- 1 Palestine, State of 99.0% compare
- 1 Uzbekistan 99.0% compare
- 1 Guyana 99.0% compare
More health data for High income (World Bank)
- Pertussis - number of reported cases 178,482 (2025)
- Diphtheria - number of reported cases 235 (2025)
- Measles - number of reported cases 25,070 (2025)
- Total tetanus - number of reported cases 205 (2025)
- Neonatal tetanus - number of reported cases 2 (2025)
- Infant mortality rate (probability of dying between birth and age 1) 4.24 (2024)
- Number of neonatal deaths 35,336 (2024)
- Thinness among children and adolescents, BMI-for-age < -2 standard 2.5% (2024)
- Under-five mortality rate 5.09 (2024)
- Neonatal mortality rate 2.79 (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in High income (World Bank)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in High income (World Bank) was 87.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in High income (World Bank)?
- The highest recorded value was 90.0% in 2019.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in High income (World Bank)?
- The lowest recorded value was 35.0% in 2008.
- How does High income (World Bank) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- High income (World Bank) ranks 2nd out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in High income (World Bank)?
- Over the last ten years it is up 20.8%. The long-run trend across the full record is rising.
- Where does this High income (World Bank) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).